IPO bound, Netcore Cloud takes majority stake in Unbxd Inc, invests close to $100 mn - one of India's largest strategic SaaS investments, to date
Netcore Cloud, a profitable SaaS company and global leader in customer communication, engagement, and retention, bets big on Personalization with its investment of close to $100 mn to acquire a majority stake in US-based, search-personalization company Unbxd Inc. It will also be infusing additional funding into Unbxd to propel the company's growth in developed markets.
Founded by Pavan Sondur and Prashant Kumar in 2012, Unbxd is a 120-member team and has built a best-in-class AI-powered Product Discovery suite. Its intelligent search solutions significantly improve retention and conversions for leading eCommerce retailers/B2C brands in the USA, UK, and Australia, including marquee brands like Mattress Firm, Express, Ashley Homestore, Home Shopping Network, Advance Auto Parts, The Children's Place, Mitre10, Kookai, and many others.
Netcore Cloud, has ranked a strong performer globally in email marketing by Forresterwave, commands 75% of India's & 50% of Asia's email traffic on its platform. With Unbxd's expertise in product discovery, the investment positions Netcore Cloud's as a leading Digital Experience Platform (DXP) globally. Leveraging Unbxd's AI-powered search expertise equips Netcore Cloud to deliver a real-time recommendation to its online eCommerce/app-first brand and retailer.
"The coming MarTech era will be defined by budget shifts from Adtech to MarTech as brands will focus more on unit economics and valuing existing customers. This will lead D2C/eCommerce brands to accelerate their spending towards delivering personalized customer experiences. Unbxd's AI/ML tech stack will empower our customers to track their shopper’s interactions with Search and implement site-wide Personalization, merchandising, along with shopper-focused recommendations. This will enable brands to optimize their entire customer journey, providing the best in class customer experience," said Kalpit Jain, Group CEO, Netcore Cloud.
"Netcore Cloud platform is growing rapidly at 40% YoY (with international markets growing 100% YoY ). We are positioned as the digital proxy in emerging markets. Added to that, this investment will enable us to get a strong foothold in the US and other developed markets as well. Furthermore, the combination of Unbxd and Netcore Cloud's capabilities will bolster our full-stack product offerings,” said Nishant Jain, Chief Strategy Officer and Head of M&A, Netcore Cloud.
He further added, “The SaaS market is very fragmented, and the era of SaaS consolidation is upon us. We intend to fast-track our growth exponentially with the Buy-Partner strategy. This is our fourth acquisition in quick succession, and we already have our eyes set on the next one.”
Pavan Sondur and Prashant, Co-founders at Unbxd, said, "Since our launch, we at Unbxd have been on a mission to solve the problem of discovery for digital commerce leveraging the power of AI. With our unique combination of personalization solutions and Netcore's robust full-stack marketing automation tech platform, it's a perfect partnership that can capture cross-selling opportunities and scale the business globally.
Netcore Cloud has confirmed that there will be no change in the company's management, as the founders and key management will continue to build and grow the company post this deal. Unbxd will operate as an independent entity.
About Netcore Cloud:
Netcore Cloud is a bootstrapped SaaS company that helps B2C brands and marketers create AI-powered new-age customer experiences at every touchpoint of a customer's journey. Netcore Cloud's full-stack marketing platform enables highly personalized digital experiences that are easily scalable and provide actionable analytics, real-time reporting, and quick to implement solutions across channels. Brands using Netcore Cloud can have a unified view of their customers and optimize their user experience.
Headquartered in Mumbai, India, with 11 offices across the USA, Singapore, Malaysia, Nigeria, Indonesia, UAE, UK, and Germany, Netcore Cloud serves 5000+ customers across the globe. It delivers 17+ billion emails and tracks 100+ billion marketing events every month. Netcore Cloud is a trusted partner across industries with some of the most respected brands like MaxLife Insurance, ICICI Bank, Standard Chartered, Flipkart, Myntra, Miss Amara, Airtel, Disney Hotstar, Canon, Puma, Tobi, EaseMyTrip, PizzaHut and McDonald's. For more information, visit https://netcorecloud.com/
Unbxd is an eCommerce product discovery platform to help online retailers provide a seamless shopping experience to customers. The company deploys self-learning AI/ML models and advanced algorithms to deliver personal recommendation and merchandising controls. Presently, the company empowers 3.5% of all US e-commerce on-site search queries spread over 150+ customers. The company has a wide presence in 40+ countries and provides intelligent site search to more than 1,200 eCommerce sites.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination
Ipsen: ASCO 2022: New Cabometyx ® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer26.5.2022 23:00:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® (cabozantinib), across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2022) to be held on 3-7 June. Data presentations will include findings in metastatic non-small cell lung cancer (NSCLC), as well as established indications of advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). These data show that the therapeutic potential of Cabometyx as a key treatment option in a broad range of tumors is continuing to be realized. Updated outcomes from the multicenter Phase Ib COSMIC-021 trial evaluating the combination of Cabometyx plus atezolizumab in an expanded patient population in metastatic NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhib
New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution26.5.2022 19:00:00 CEST | Press release
Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new Better Dispensing™ How-To Video series. These three highly educational videos presented by EFD application specialist, Tom Muccino, provide best practices for choosing between contact dispensing and non-contact (jet) dispensing, and how to select the best jetting valve for a manufacturing application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510006079/en/ xQR41 Series MicroDot™ needle valve (left) and PICO Pµlse XP jet valve (right). (Photo: Business Wire) “One of the main differences is that with jetting, your valve never touches the surface of the part. Instead, your fluid “flies” or “jets” out of the valve, which is above the part,” Muccino explains in the first video. “This makes jetting perfect for fragile or complex parts.” Nordson EFD provides a wide range of contact and non-contact (jet
Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA26.5.2022 18:17:00 CEST | Press release
On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio). “Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, chan
Merck to Present Latest Research From Oncology Portfolio at ASCO 202226.5.2022 18:00:00 CEST | Press release
Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN). “We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom